Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala(Boston Medical Center), David C. Seldin(Boston University), Jerome B. Zeldis(University of California, Davis), Kathleen T. Finn(Boston University), Daniel G. Wright(University of Washington), Salli Fennessey(Boston University), Martha Skinner(Boston University), Michael Rosenzweig(Boston University)
Cited by 258
Related Papers
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Efficacy of Lenalidomide in Myelodysplastic Syndromes
|New England Journal of Medicine|2005|874
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615
Systemic immunoglobulin light chain amyloidosis
|Nature Reviews Disease Primers|2018|550